Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B. Apolo, Jonathan E. Rosenberg, William Y. Kim et al.|New England Journal of Medicine|2024Cited by 145
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancerDana E. Rathkopf, Andrew J. Armstrong, Manish R. Patel et al.|Annals of Oncology|2024Cited by 66